Skip to main content

Table 2 Dose of lanthanum carbonate at the end of the dose-titration phase; safety set

From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

Dose, mg/day

Dose-titration phase (n= 39)

Parallel-group phase

Lanthanum carbonate (n= 10)

Placebo (n= 11)

375

5 (12.8)

1 (10.0)

0 (0.0)

750

11 (28.2)

3 (30.0)

4 (36.4)

1500

14 (35.9)

3 (30.0)

4 (36.4)

2250

9 (23.1)

3 (30.0)

3 (27.3)

  1. Data are presented as n (%).
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us